Furthermore, the tight connection between METTL3 acetylation and node metastasis indicates that targeting METTL3 deacetylation by ASP/NAM may provide therapeutic advantages in breast cancer patients with node metastasis (Fig. 8). This evidence concerns the gene METTL3 and breast cancer.